| Subject |
Mechanism of ON101 cream for prevention and treatment of radiation dermatitis has been published in the SCI journal, Life Sciences |
|
1.Date of occurrence of the event:2025/06/10
2.Company name:ONENESS BIOTECH CO., LTD
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:
After the launch of ON101 Cream, various possible indications have been continuously developed, and ON101 has been proven that it can counteracts oxidative stress and inflammation in radiation dermatitis through its innovative mechanism of action of inhibiting Keap1 and activating Nrf2, effectively relieving radiation-induced skin damage, and showing good therapeutic potential.
The study results have been accepted and published by the prestigious SCI journal: Life Sciences (Impact Factor: 5.2).
6.Countermeasures:None
7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):
(1)ON101 is a topical cream developed by Oneness Biotech Co., Ltd. and marketed globally. It complies with the regulations of various countries and takes advantage of the natural product formula to enable market access via new drug or medical device pathway. Its indications include acute and chronic wounds, post-surgical wounds, and scar management, etc. depending on the region.
(2)ON101 can modulate the Keap1/Nrf2 signaling pathway to exert antioxidant and anti-inflammatory effects, thereby counteracting the oxidative stress and inflammation in radiation-induced dermatitis. Compared with steroid treatment, ON101 can reverse the thickening and fibrosis of the dermis caused by radiation, thus, restoring the skin architecture and elasticity. At the same time, it enhances the expression of key genes involved in DNA
damage repair and skin regeneration, including EGFR, VIM and CTNNB1, highlighting its excellent regenerative potential. These demonstrate that ON101 has clinical potential for the prevention and treatment of radiation-induced dermatitis.
(3)The article is available online on Life Sciences:
https://www.sciencedirect.com/science/article/abs/pii/S0024320525004230?via%3Dihub
|
